title: Pharmacokinetic interaction between oltipraz and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) after single intravenous and oral administration to rats.
abstract: The aim of this study was to report the pharmacokinetic interaction between oltipraz (50 mg kg(-1)) and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB, 10 mg kg(-1)) after single intravenous and oral administration to rats. After intravenous administration of oltipraz plus DDB, the area under the plasma concentration-time curve from time zero to time infinity (AUC) of oltipraz was significantly greater (1440 vs 1740 microg min mL(-1)) than that after oltipraz alone. This was not due to slower clearances of oltipraz after oltipraz plus DDB since the total body, renal and nonrenal clearances were comparable between the two groups of rats. It could be due to a decrease in tissue binding of oltipraz by DDB. The apparent volume of distribution at steady state (Vd(ss)) of DDB was significantly smaller (7060 vs 4650 mL kg(-1)) than after oltipraz alone. After oral administration of oltipraz plus DDB, the AUC of olitpraz was also significantly greater (479 vs 583 microg min mL(-1)) than that after oltipraz alone. This was not due to increased absorption of oltipraz from the rat gastrointestinal tract after oltipraz plus DDB but again could be due to a decrease in Vd(ss) of oltipraz by DDB. However, after both intravenous and oral administration, the pharmacokinetic parameters of DDB were comparable between DDB alone and DDB plus oltipraz, indicating that oltipraz did not greatly affect the pharmacokinetics of DDB in rats.
authors: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Kwanak-Gu, Korea.
authors: Soo Kyung
authors: SK
authors: Bae
authors: Eun Jung
authors: EJ
authors: Kim
authors: Suk Jae
authors: SJ
authors: Chung
authors: Sang Geon
authors: SG
authors: Kim
authors: Myung Gull
authors: MG
authors: Lee
mesh_terms: D000284:Administration, Oral; D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D019540:Area Under Curve; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003998:Dicarboxylic Acids / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D004347:Drug Interactions; D007275:Injections, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D020011:Protective Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D011719:Pyrazines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013871:Thiones; D013876:Thiophenes; D014018:Tissue Distribution
chemical_list: D016588:Anticarcinogenic Agents; D001713:Biphenyl Compounds; D003998:Dicarboxylic Acids; D020011:Protective Agents; D011719:Pyrazines; D013871:Thiones; D013876:Thiophenes; C510843:dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate; C026209:oltipraz